Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 May;93(5):2740-2768.
doi: 10.1002/jmv.26836. Epub 2021 Feb 23.

Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves

Rami M Elshazli  1 , Adam Kline  2 , Abdelaziz Elgaml  3   4 , Mohamed H Aboutaleb  5 , Mohamed M Salim  5   6 , Mahmoud Omar  7 , Ruhul Munshi  8 , Nicholas Mankowski  2 , Mohammad H Hussein  7 , Abdallah S Attia  7 , Eman A Toraih  7   9 , Ahmad Settin  10 , Mary Killackey  7 , Manal S Fawzy  11   12 , Emad Kandil  8
Affiliations
Meta-Analysis

Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves

Rami M Elshazli et al. J Med Virol. 2021 May.

Abstract

A meta-analysis was performed to identify patients with coronavirus disease 2019 (COVID-19) presenting with gastrointestinal (GI) symptoms during the first and second pandemic waves and investigate their association with the disease outcomes. A systematic search in PubMed, Scopus, Web of Science, ScienceDirect, and EMBASE was performed up to July 25, 2020. The pooled prevalence of the GI presentations was estimated using the random-effects model. Pairwise comparison for the outcomes was performed according to the GI manifestations' presentation and the pandemic wave of infection. Data were reported as relative risk (RR), or odds ratio and 95% confidence interval. Of 125 articles with 25,252 patients, 20.3% presented with GI manifestations. Anorexia (19.9%), dysgeusia/ageusia (15.4%), diarrhea (13.2%), nausea (10.3%), and hematemesis (9.1%) were the most common. About 26.7% had confirmed positive fecal RNA, with persistent viral shedding for an average time of 19.2 days before being negative. Patients presenting with GI symptoms on admission showed a higher risk of complications, including acute respiratory distress syndrome (RR = 8.16), acute cardiac injury (RR = 5.36), and acute kidney injury (RR = 5.52), intensive care unit (ICU) admission (RR = 2.56), and mortality (RR = 2.01). Although not reach significant levels, subgroup-analysis revealed that affected cohorts in the first wave had a higher risk of being hospitalized, ventilated, ICU admitted, and expired. This meta-analysis suggests an association between GI symptoms in COVID-19 patients and unfavorable outcomes. The analysis also showed improved overall outcomes for COVID-19 patients during the second wave compared to the first wave of the outbreak.

Keywords: COVID-19; GIT; SARS-CoV-2; meta-analysis; pandemic.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
Selection of eligible studies and their geographic region. (A) Flowchart for systematic literature search (B) Mapping the geographic distribution of the studies
Figure 2
Figure 2
Prevalence of gastrointestinal manifestations. (A) The proportion of patients with COVID‐19 presenting with gastrointestinal symptoms. One‐arm meta‐analysis was applied. Overall proportion and confidence intervals are shown. Subgroup analysis was performed stratifying studies by the date of publication (during the first wave; < May 15, or during the second wave; > May 15) and by geographical regions (Asia, Europe, America, and Mexico). (B) The proportion of gastrointestinal symptoms in COVID‐19 cohorts. (C) Prevalence of fecal shedding confirmed by fecal RNA RT‐PCR. (D) Duration of viral shedding (days). CI, confidence interval; COVID‐19, coronavirus disease 2019; RT‐PCR, reverse‐transcription polymerase chain reaction
Figure 3
Figure 3
Subgroup analysis for pooled one‐arm meta‐analysis of COVID‐19 outcomes by the pandemic wave. Odds ratio and 95% confidence intervals were reported. p values comparing the first and second waves were estimated using Student's t‐test. ARDS, acute respiratory distress syndrome; COVID‐19, coronavirus disease 2019
Figure 4
Figure 4
Subgroup analysis for pooled pairwise comparison analysis of coronavirus diease‐2019 outcomes by the pandemic wave. (A) Clinical outcomes. (B) Admission outcomes were compared between cohorts presented with versus without gastrointestinal manifestations. CI, confidence interval
See this image and copyright information in PMC

References

    1. Wong SH, Lui RNS, Sung JJY. Covid‐19 and the digestive system. J Gastroenterol Hepatol. 2020;35(5):744‐748. - PubMed
    1. Goh KJ, Kalimuddin S, Chan KS. Rapid progression to acute respiratory distress syndrome: review of current understanding of critical illness from coronavirus disease 2019 (COVID‐19) infection. Ann Acad Med Singapore. 2020;49:108‐118. - PubMed
    1. Terpos E, Ntanasis‐Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID‐19. Am J Hematol. 2020;95:834‐847. - PMC - PubMed
    1. Pan F, Yang L, Li Y, et al. Factors associated with death outcome in patients with severe coronavirus disease‐19 (COVID‐19): a case‐control study. Int J Med Sci. 2020;17(9):1281‐1292. - PMC - PubMed
    1. Tian Y, Rong L, Nian W, He Y. gastrointestinal features in COVID‐19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51(9):843‐851. - PMC - PubMed